Pieris Pharmaceuticals leverages advanced protein engineering capabilities to develop innovative therapeutics, particularly in the field of immuno-oncology. The company focuses on creating bispecific programs that target specific molecular pathways, such as 4-1BB, which is crucial for enhancing immune responses against cancer. Their partnerships with major industry players like Pfizer and Boston Pharmaceuticals allow Pieris to share the financial burden of development while providing opportunities for significant future milestones and royalties as these programs progress through clinical trials.

The company's pipeline includes several promising candidates, such as PRS-346/SGN-BB228 and PRS-342/BOS-342, which are currently in various stages of clinical development. These candidates are designed to engage multiple targets, thereby enhancing therapeutic efficacy and improving patient outcomes. By combining their expertise in protein engineering with strategic collaborations, Pieris aims to deliver superior clinical results and address unmet medical needs in oncology.

United States

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.

Cancer

Lung Diseases

Pieris Pharmaceuticals

Solid tumor/s

Pieris Pharmaceuticals’ PRS-344/S095012 is a 4-1BB/PD-L1 &nbsp;bispecific being developed in collaboration with Servier. PRS-344 &nbsp;consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin® &nbsp;proteins genetically fused to each arm of the antibody’s C-terminal &nbsp;heavy chain. 4-1BB is a co-stimulatory receptor belonging to the TNFR &nbsp;superfamily.
Clustering of 4-1BB on the surface of T cells leads to T cell &nbsp;activation, proliferation, and cytokine secretion. The mode of action of &nbsp;PRS-344 is to promote 4-1BB clustering by bridging 4-1BB-positive T &nbsp;cells with PD-L1-positive tumor cells, providing a potent co-stimulatory &nbsp;signal to tumor antigen-specific T cells. PRS-344 is intended to &nbsp;localize 4-1BB activation in the tumor in a PD-L1-dependent manner.

PRS-344/S095012

Asthma

Lung disease

PRS-060/AZD1402, an Anticalin protein potently engaging IL-4Rα, is being developed for patients suffering from moderate to severe asthma, many of whom are not able to control their asthma well with currently available medications. In a large proportion of asthma patients, the Th2 pathway plays an important role. IL-4 and IL-13 are the main cytokines involved in Th2-mediated asthma. Both signal via IL-4Rα, making this receptor a cornerstone intervention point. PRS-060/AZD1402 differentiates from antibody approaches through patient-convenient, inhaled delivery directly into the lungs, potentially resulting in efficacy and tolerability benefits. The local delivery may allow for lower doses than systemically administered antibodies, potentially also resulting in a significant cost of goods advantage over those therapies. Pieris has demonstrated proof of concept in animals as well as feasibility for pulmonary delivery with PRS-060/AZD1402.

Elarekibep (PRS-060/AZD1402)

PRS-343 is a bivalent, bispecific fusion protein targeting CD137 (4-1BB) and HER2 comprising an agonistic CD137-targeting Anticalin genetically linked to a HER2-targeting antibody. CD137 is a key costimulatory immunoreceptor and a member of the TNF-receptor (TNFR) superfamily.

Cinrebafusp Alfa (PRS-343) (4-1BB/HER2 Bispecific)

Idiopathic pulmonary fibrosis

Inhaled Anticalin protein targeting connective tissue growth factor (CTGF)

Pieris Pharmaceuticals

Company Details